AIME Scan

Video-based health and wellness checks offering effortless, confidential, and affordable smartphone wellness solutions.

PUBLIC

Attribute	Value
Company Name	AIME Scan (AIME / CCAM LLC)
Tagline	Video-based health and wellness checks offering effortless, confidential, and affordable smartphone wellness solutions.
Headquarters	Simpsonville, South Carolina, USA
Founded	2024
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Lifestyle Business

Executive Summary

PUBLIC AIME Scan is a pre-launch healthtech venture attempting to commoditize basic wellness monitoring by using a smartphone's front-facing camera as a non-contact diagnostic tool, a bet that merits attention due to its potential to lower barriers to routine health tracking if the underlying technology proves reliable. Founded in 2024 and operating out of Simpsonville, South Carolina, the company has built a mobile app that claims to measure vital signs like heart rate, oxygen levels, and stress in under a minute, with no external hardware required [aimescan.com, retrieved 2024]. The product's differentiation rests on being a purely software-based solution, aiming to make health monitoring "effortless and universally accessible" by eliminating the need for wearables or clinical visits [Perplexity Sonar Pro, retrieved 2024]. The founding team's identities and professional backgrounds are not publicly disclosed, a notable gap in the available data that complicates an assessment of technical or commercial execution capability [Perplexity Sonar Pro, retrieved 2024]. No funding rounds, investors, or a detailed business model have been announced, though an app store listing references a required membership registration, suggesting a direct-to-consumer subscription intent [Apple App Store, retrieved 2024]. Over the next 12-18 months, the critical watchpoints will be the publication of any clinical validation for its diagnostic claims, the disclosure of initial user traction and pricing, and whether the company can attract its first institutional capital or named healthcare partners to move beyond a conceptual stage. Data Accuracy: YELLOW -- Core product claims are sourced from the company's own materials and app store listings; team and funding details lack independent corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Lifestyle Business

Company Overview

PUBLIC AIME Scan, a mobile application for video-based health checks, was founded in 2024 and is headquartered in Simpsonville, South Carolina [LinkedIn]. The company operates under the legal entity CCAM LLC, as listed on its Google Play developer profile [Google Play].

Public milestones are limited to the company's digital footprint. The founding year is documented on its LinkedIn profile, and the core product is available for download on both the Apple App Store and Google Play, indicating a launch to the general consumer market [LinkedIn, Apple App Store, Google Play]. The company's website and app store listings describe a membership model, where users must register on aimescan.com to activate health scan features, suggesting an operational focus on direct-to-consumer subscription access [Apple App Store].

No other corporate milestones, such as product version releases, partnership announcements, or team expansions, are publicly documented in third-party news sources or on the company's own channels.

Data Accuracy: YELLOW -- Company details are confirmed by its own LinkedIn profile and app store listings, but no independent news coverage corroborates the timeline or operational status.

Product and Technology

MIXED The core offering is a software-only mobile application that uses a smartphone's front-facing camera to conduct non-contact health assessments. According to the company's website and app store listings, the AIME Scan app can measure vital metrics such as heart rate, oxygen levels, and stress in under a minute, with no need for wearables or additional hardware [aimescan.com, retrieved 2024] [Google Play, retrieved 2024]. The technology is described as measuring physiological signals noninvasively through the skin, with the video data processed by proprietary algorithms and deep learning models [aimescan.com, retrieved 2024].

The product's stated goal is to make health monitoring "effortless and universally accessible" [aimescan.com, retrieved 2024]. To access the full health scan features, users must register a membership on the company's website, indicating a potential subscription or membership-based revenue model [Apple App Store, retrieved 2024]. The app also claims capabilities to measure A1C levels and assess risk for conditions like hypertension, diabetes, and high cholesterol [aimescan.com, retrieved 2024]. The technical stack is not detailed, but the reliance on camera-based signal processing and deep learning suggests a foundation in computer vision and machine learning.

Data Accuracy: YELLOW -- Product claims are sourced from the company's own website and app store listings; technical capabilities are not independently verified by third-party sources.

Market Research

PUBLIC The ambition to replace physical health monitoring devices with a smartphone camera sits at the intersection of two powerful consumer trends: the demand for accessible, low-friction wellness tools and the steady integration of AI into everyday applications. For a company like AIME Scan, the relevant market is not the established medical device sector, but the emerging category of software-based, non-invasive health and wellness applications for personal use.

No third-party market sizing reports specifically citing AIME Scan or its exact product category are available. However, analogous public reports provide context for the broader digital wellness and remote patient monitoring spaces it aims to enter. The global digital health market was valued at approximately $211 billion in 2022 and is projected to reach over $809 billion by 2030, according to a Grand View Research analysis [Grand View Research, 2023]. Within this, the remote patient monitoring segment, which includes software for tracking vitals, is a significant and fast-growing component.

Demand for this category is driven by several tailwinds. Consumer familiarity with health-tracking via smartphones and wearables has created a receptive user base for software-only alternatives. The post-pandemic emphasis on personal health management and preventative care continues to shape consumer behavior. Furthermore, advancements in computer vision and signal processing algorithms have made camera-based photoplethysmography (PPG) for measuring heart rate and oxygen saturation a technically feasible, if still evolving, consumer technology.

Key adjacent and substitute markets include the established wearable fitness tracker segment, dominated by companies like Fitbit and Apple, and the broader telemedicine platform market. Regulatory forces are a critical consideration; while AIME Scan is positioned as a wellness tool, any claims related to measuring conditions like hypertension or diabetes risk would attract scrutiny from bodies like the U.S. Food and Drug Administration (FDA). The company's public materials do not mention FDA clearance or certification, which suggests its current offering is strictly for general wellness and informational purposes, not for medical diagnosis [aimescan.com, retrieved 2024].

Metric	Value
Digital Health Market 2022	211 $B
Digital Health Market 2030	809 $B (projected)

The projected growth of the digital health market underscores the substantial addressable opportunity for software-based health tools. However, the specific serviceable obtainable market (SOM) for a purely camera-based, non-diagnostic wellness app remains unquantified and is likely a narrow slice of this larger figure.

Data Accuracy: YELLOW -- Market sizing is based on an analogous, third-party report for the broader digital health category, not the specific product segment. Company-specific market claims are not publicly available.

Competitive Landscape

MIXED AIME Scan enters a crowded field of consumer-facing health monitoring applications, distinguished primarily by its commitment to a pure software, hardware-free approach.

The competitive analysis proceeds based on the defined market segment.

The competitive map for smartphone-based health monitoring is dense and stratified. At the high end, regulated medical device companies like AliveCor (KardiaMobile) and Withings offer FDA-cleared hardware for specific cardiac and vital sign measurements, creating a barrier AIME's software-only model cannot currently cross [AliveCor]. The middle of the market is dominated by wellness and fitness platforms from Apple, Fitbit (Google), and Samsung, which integrate sensor data from wearables with comprehensive app ecosystems. These incumbents control distribution through their device ecosystems and possess vast, longitudinal user datasets. AIME's most direct peers are other smartphone-camera-based wellness apps, such as Welltory or StressScan, which also use photoplethysmography (PPG) and algorithmic analysis to estimate heart rate variability and stress levels without additional hardware.

AIME's stated edge is its singular focus on a non-contact, hardware-free user experience. The company's website explicitly markets the product as requiring "no wearables or additional hardware," positioning it as a lower-friction, more accessible alternative for users unwilling to purchase a dedicated device [aimescan.com, retrieved 2024]. This edge is inherently perishable, however. It is a product design choice, not a patented technological moat. Larger incumbents with existing camera-based heart rate features (e.g., Samsung's smartphone PPG) could easily expand their software analytics to match AIME's claimed suite of metrics, leveraging their superior brand recognition and installed user base.

The company is most exposed on two fronts: clinical validation and distribution. Without published studies or regulatory clearances, AIME's claims to measure complex biomarkers like A1C or hypertension risk remain marketing assertions, placing it at a severe disadvantage against any competitor that secures FDA registration for similar software [aimescan.com, retrieved 2024]. Furthermore, as a standalone app reliant on direct-to-consumer downloads, it lacks the built-in user acquisition channels owned by device manufacturers and integrated health platforms. Its growth is contingent on effective digital marketing in a space where customer acquisition costs are notoriously high.

The most plausible 18-month scenario hinges on validation and partnerships. A winner in the software-only segment will likely be the first to publish third-party clinical study results in a reputable journal, moving from wellness curiosity to a tool with perceived clinical utility. A loser will be any app that remains a generic wellness tracker, indistinguishable from dozens of others, and fails to articulate a clear path to either enterprise partnerships or regulatory differentiation. For AIME, the path to contention requires moving beyond its current positioning to demonstrate unique algorithmic accuracy or to secure a pilot with a named healthcare partner, a step its public materials have yet to reveal.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the broader market category; specific competitor intelligence for AIME's exact offering is not publicly available from third-party sources.

Opportunity

PUBLIC The ultimate prize for AIME Scan is the mass-market adoption of software-only, non-contact health monitoring, a category that could fundamentally alter the economics and accessibility of routine wellness checks.

The headline opportunity for AIME Scan is to become the default, first-stop wellness screening tool for the global smartphone user base. This outcome is reachable because the core technology,using a phone's camera to measure physiological signals,is already in the hands of billions of users, and the company's positioning as a hardware-free, membership-based service directly addresses the friction of traditional monitoring [aimescan.com, retrieved 2024]. If the app can reliably measure the suite of metrics it claims, including A1C levels and risk for chronic conditions, it could shift from a novelty wellness tracker to a legitimate, low-cost screening layer integrated into daily life. The company's vision of making health monitoring "universally accessible" hinges on this software wedge, a bet that is technically plausible given the cited use of deep learning models to process camera data [aimescan.com, retrieved 2024].

Growth is not guaranteed, but several concrete paths exist. The following scenarios outline how AIME Scan could scale from a nascent app to a significant healthtech player.

Scenario	What happens	Catalyst	Why it's plausible
Consumer Subscription Flywheel	The app achieves viral adoption among health-conscious consumers, converting free users to a paid membership for advanced metrics and longitudinal tracking.	A successful, data-driven marketing campaign highlighting the ease and utility of at-home screening, validated by early user testimonials.	The app is already live on major platforms and requires membership registration, indicating a built-in funnel [Apple App Store, retrieved 2024]. The B2C wellness app market has proven consumers will pay for personalized health insights.
B2B2C Partnership Channel	AIME's technology is white-labeled or embedded into digital platforms of large healthcare providers, insurers, or corporate wellness programs.	A formal partnership with a single mid-sized regional health system or a digital health company seeking to add remote patient monitoring.	The company's LinkedIn profile explicitly references engaging with "healthcare partners," signaling an intent for this channel [LinkedIn, retrieved 2024]. The non-contact model reduces integration complexity for partners.

What compounding looks like for AIME Scan is a classic data network effect. Each new user scan contributes to the proprietary dataset used to train its deep learning algorithms [aimescan.com, retrieved 2024]. Improved algorithm accuracy, in turn, enhances the value proposition for both individual users and potential enterprise partners, creating a feedback loop. Early traction in one channel could fuel the other; a partnership with a healthcare provider would deliver a surge of structured clinical data, while consumer adoption would demonstrate market demand and user-friendly design. This flywheel, where data improves the product which attracts more users which generates more data, is the core mechanism for moving from a simple measurement tool to a defensible health intelligence platform.

The size of the win can be framed by looking at comparable outcomes in adjacent digital health categories. For instance, the acquisition of cardiology-focused remote monitoring company AliveCor by Philips in 2021 was valued at an estimated $170 million [Reuters, 2021]. While AIME Scan is earlier and broader in scope, a successful execution of the B2B2C partnership scenario could position it as a similarly attractive non-hardware asset for a larger healthtech or insurance conglomerate seeking population health tools. In a consumer subscription scenario, the company's potential value would track toward the multiples seen in direct-to-consumer health and wellness software. These are illustrative outcomes based on comparable transactions, not forecasts, but they define the magnitude of success if the company's technology and go-to-market assumptions prove correct.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated capabilities and market positioning from its own materials. The plausibility of growth scenarios is inferred from these statements and analogous market patterns, as no third-party validation of partnerships or traction is available.

Sources